Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 67 (Suppl 3) , iii2-iii25
- https://doi.org/10.1136/ard.2008.100834
Abstract
This consensus was prepared from the perspective of the treating physician.Keywords
This publication has 329 references indexed in Scilit:
- A pilot study to evaluate the safety and efficacy of the long‐acting interleukin‐1 inhibitor rilonacept (interleukin‐1 trap) in patients with familial cold autoinflammatory syndromeArthritis & Rheumatism, 2008
- Rituximab therapy for juvenile-onset systemic lupus erythematosusPediatric Nephrology, 2007
- Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics RegisterArthritis & Rheumatism, 2007
- Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis & Rheumatism, 2007
- Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical centerArthritis Care & Research, 2005
- Prolonged remission in adult-onset Still’s disease with etanerceptClinical Rheumatology, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodiesMuscle & Nerve, 2003
- Sustained response to tumor necrosis factor α–blocking agents in two patients with SAPHO syndromeArthritis & Rheumatism, 2002
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002